BRPI0815769A2 - Ebi3, dlx5, nptx1 e cdkn3 como genes alvo da terapia e diagnóstico de câncer de pulmão - Google Patents

Ebi3, dlx5, nptx1 e cdkn3 como genes alvo da terapia e diagnóstico de câncer de pulmão

Info

Publication number
BRPI0815769A2
BRPI0815769A2 BRPI0815769A BRPI0815769A BRPI0815769A2 BR PI0815769 A2 BRPI0815769 A2 BR PI0815769A2 BR PI0815769 A BRPI0815769 A BR PI0815769A BR PI0815769 A BRPI0815769 A BR PI0815769A BR PI0815769 A2 BRPI0815769 A2 BR PI0815769A2
Authority
BR
Brazil
Prior art keywords
lung cancer
cdkn3
nptx1
dlx5
ebi3
Prior art date
Application number
BRPI0815769A
Other languages
English (en)
Inventor
Nakamura Yusuke
Daigo Yataro
Nakatsuru Shuichi
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of BRPI0815769A2 publication Critical patent/BRPI0815769A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Abstract

MOLÉCULA DE DUPLA FITA, VETOR, ANTICORPO, COMPOSIÇÕES, KITS, USOS DA REFERIDA MOLÉCULA E DO REFERIDO ANTICORPO, MÉTODOS PARA DIAGNOSTICAR, AVALIAR OU DETERMINAR PROGNÓSTICO DE UM PACIENTE COM CÂNCER DE PULMÃO E PARA CLASSIFICAR UM COMPOSTO CANDIDATO PARA TRATAR OU PREVENIR CÂNCER DE PULMÃO. A presente invenção refere-se a métodos para tratamento de câncer de pulmão pela administração de molécula de dupla fita contra uma ou mais dos genes EBI3, DLX5, NPTX1, CDKN3 ou EF-1 delta ou de composições, vetores ou células contendo tal molécula de dupla fita. A presente invenção também caracteriza métodos para diagnóstico de câncer de pulmão, especialmente NSCLC ou SCLC, usando um ou mais genes superexpressos selecionados entre EBI3, DLX5, NPTX1, CDKN3 e/ou EF-1 delta. Também são revelados métodos de identificação de compostos para tratar e prevenir câncer de pulmão, usando como um índice seu efeito na superexpressão de um ou mais de EBI3, DLX5, NPTX1, CDKN3 e/ou EF-1 delta no câncer de pulmão, na função de proliferação celular de um ou mais de EBI3, DLX5, NPTX1, CDKN3 e/ou EF-1 delta ou na interação entre CDKN3 e VRS, EF-1 gama e/ou EF-1 delta.
BRPI0815769A 2007-08-24 2008-08-21 Ebi3, dlx5, nptx1 e cdkn3 como genes alvo da terapia e diagnóstico de câncer de pulmão BRPI0815769A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95795607P 2007-08-24 2007-08-24
US97736007P 2007-10-03 2007-10-03
PCT/JP2008/065352 WO2009028580A1 (en) 2007-08-24 2008-08-21 Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis

Publications (1)

Publication Number Publication Date
BRPI0815769A2 true BRPI0815769A2 (pt) 2017-08-08

Family

ID=40387295

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815769A BRPI0815769A2 (pt) 2007-08-24 2008-08-21 Ebi3, dlx5, nptx1 e cdkn3 como genes alvo da terapia e diagnóstico de câncer de pulmão

Country Status (10)

Country Link
US (1) US20110152345A1 (pt)
EP (1) EP2198021A4 (pt)
JP (1) JP2010536366A (pt)
KR (1) KR20100075857A (pt)
CN (1) CN101835894A (pt)
BR (1) BRPI0815769A2 (pt)
CA (1) CA2697513A1 (pt)
RU (1) RU2010111120A (pt)
TW (1) TW200920406A (pt)
WO (1) WO2009028580A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
EP2305811A1 (en) * 2005-07-27 2011-04-06 Oncotherapy Science, Inc. Method of diagnosing smal cell lung cancer
WO2011145085A2 (en) * 2010-05-21 2011-11-24 Procognia (Israel) Ltd Novel antibodies and methods of use for the treatment and diagnosis of cancer
US20130078642A1 (en) * 2010-06-03 2013-03-28 Porto Conte Richerche S.R.L. Biomarkers for lung neuroendocrine tumors
WO2012054732A2 (en) * 2010-10-20 2012-04-26 Rush University Medical Center Lung cancer tests
WO2012158780A2 (en) * 2011-05-16 2012-11-22 The Regents Of The University Of Michigan Lung cancer signature
US9753037B2 (en) 2013-03-15 2017-09-05 Rush University Medical Center Biomarker panel for detecting lung cancer
US20150038365A1 (en) * 2013-08-01 2015-02-05 Meso Scale Technologies, Llc Lung cancer biomarkers
WO2015088947A1 (en) 2013-12-09 2015-06-18 Rush University Medical Center Biomarkers of rapid progression in advanced non-small cell lung cancer
KR101601943B1 (ko) 2014-02-28 2016-03-09 이화여자대학교 산학협력단 난소암 환자의 항암제 치료 반응성 예측을 위한 마커 uchl1
KR101601942B1 (ko) 2014-02-28 2016-03-09 이화여자대학교 산학협력단 난소암 환자의 항암제 치료 반응성 예측을 위한 마커 tet1
KR101601941B1 (ko) 2014-02-28 2016-03-09 이화여자대학교 산학협력단 난소암 환자의 항암제 치료 반응성 예측을 위한 마커 mta3
KR101583673B1 (ko) 2014-02-28 2016-01-08 이화여자대학교 산학협력단 난소암 환자의 항암제 치료 반응성 예측을 위한 마커 dlx5
CN109406782A (zh) * 2016-05-11 2019-03-01 卢氏实验室公司 一种快速诊断和监控肺癌的免疫层析检测条及其制备方法
CN108182346B (zh) * 2016-12-08 2021-07-30 杭州康万达医药科技有限公司 预测siRNA针对某类细胞的毒性的机器学习模型的建立方法及其应用
CA3073254A1 (en) * 2017-08-21 2019-02-28 Savicell Diagnostic Ltd. Methods of diagnosing and treating lung cancer
JP7312451B2 (ja) * 2018-01-26 2023-07-21 国立大学法人東海国立大学機構 受容体タンパク質を標的とする治療薬、検査薬、受容体タンパク質に結合する抗体、及び分子標的薬のスクリーニング方法
SG10201802979VA (en) * 2018-04-10 2019-11-28 Kah Meng Lim Immunological extract and method of production
CN110938129B (zh) * 2019-11-08 2021-07-13 上海交通大学 一种生物活性多肽sklvpvgygirkl及其制备方法和应用
CN111116744A (zh) * 2020-01-07 2020-05-08 长江大学 哺乳动物eEF1Bα蛋白磷酸化Ser106位点的特异性抗体的制备方法及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
DE69333082T2 (de) 1992-02-11 2004-05-06 Cell Genesys, Inc., Foster City Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
ES2434840T3 (es) 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
WO1997013589A1 (en) * 1995-10-10 1997-04-17 Minnesota Mining And Manufacturing Company Corrosion protection coating system
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
CA2444854A1 (en) 2001-04-26 2002-11-07 Avidia Research Institute Combinatorial libraries of monomer domains
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20040038877A1 (en) * 2001-10-02 2004-02-26 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
AU2003249012A1 (en) * 2002-09-30 2004-04-23 Japan As Represented By The President Of The University Of Tokyo Genes and polypeptides relating to human myeloid leukemia
WO2004094636A1 (en) * 2003-04-24 2004-11-04 Galapagos Genomics N.V. Effective sirna knock-down constructs
EP2343384A3 (en) * 2004-03-23 2012-01-04 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancer
LT1781787T (lt) 2004-08-23 2017-07-25 Sylentis S.A.U. Akių sutrikimų, charakterizuojamų padidintu vidiniu akispūdžiu, gydymas sirnr pagalba
JP5109131B2 (ja) * 2005-02-10 2012-12-26 オンコセラピー・サイエンス株式会社 膀胱癌を診断する方法
WO2006118308A1 (ja) * 2005-05-02 2006-11-09 Toray Industries, Inc. 食道ガン及び食道ガン転移診断のための組成物及び方法
WO2007086915A2 (en) * 2005-05-12 2007-08-02 Applied Genomics, Inc. Reagents and methods for use in cancer diagnosis, classification and therapy
EP2305811A1 (en) * 2005-07-27 2011-04-06 Oncotherapy Science, Inc. Method of diagnosing smal cell lung cancer
ES2379805T3 (es) * 2005-07-27 2012-05-03 Oncotherapy Science, Inc. ECT2 como diana terapéutica del cáncer de esófago
DE102005049800B4 (de) * 2005-10-18 2009-09-17 Johannes-Gutenberg-Universität Mainz Verfahren zur Auffindung von Inhibitoren des Epstein-Barr-Virus-induzierten Gens 3 (EBI 3) und deren Verwendungen bei der Behandlung von metastasierenden Tumoren und allergischem Asthma
CA2949753A1 (en) * 2005-12-22 2007-07-05 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
WO2008023840A2 (en) * 2006-08-25 2008-02-28 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer

Also Published As

Publication number Publication date
CA2697513A1 (en) 2009-03-05
US20110152345A1 (en) 2011-06-23
TW200920406A (en) 2009-05-16
JP2010536366A (ja) 2010-12-02
CN101835894A (zh) 2010-09-15
EP2198021A1 (en) 2010-06-23
RU2010111120A (ru) 2011-09-27
KR20100075857A (ko) 2010-07-05
WO2009028580A1 (en) 2009-03-05
EP2198021A4 (en) 2011-01-19

Similar Documents

Publication Publication Date Title
BRPI0815769A2 (pt) Ebi3, dlx5, nptx1 e cdkn3 como genes alvo da terapia e diagnóstico de câncer de pulmão
Janin et al. Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program
Dickens et al. Principles of cancer treatment by chemotherapy
Wang et al. Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax
Qu et al. Prognostic value of immune-related genes in the tumor microenvironment of lung adenocarcinoma and lung squamous cell carcinoma
Lu et al. Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer
Sun et al. Role of insulin-like growth factor-1 signaling pathway in cisplatin-resistant lung cancer cells
Li et al. miR-449a suppresses LDHA-mediated glycolysis to enhance the sensitivity of non-small cell lung cancer cells to ionizing radiation
Krivak et al. Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer
BR112014015152A2 (pt) métodos e materiais para a avaliação da perda de heterozigosidade
Horne et al. Why imatinib remains an exception of cancer research
Tracey et al. Transplantation conditioning regimens and outcomes after allogeneic hematopoietic cell transplantation in children and adolescents with acute lymphoblastic leukemia
Nabavi et al. Switching off malignant mesothelioma: exploiting the hypoxic microenvironment
Huetter-Kroenke et al. Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy
Cheng et al. Comprehensive circular RNA profiling identifies CircFAM120A as a new biomarker of hypoxic lung adenocarcinoma
Urtasun et al. Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors
Chen et al. A functional variant at the miR-214 binding site in the methylenetetrahydrofolatereductase gene alters susceptibility to gastric cancer in a Chinese Han population
Wang et al. Association of topoisomerase II (TOP2A) and dual-specificity phosphatase 6 (DUSP6) single nucleotide polymorphisms with radiation treatment response and prognosis of lung cancer in Han Chinese
CY1115258T1 (el) Μεθοδοι και χρησεις που περιλαμβανουν τις γενετικες παρεκκλισεις του ναv3 και την παρεκκλινουσα εκφραση πολλαπλων γονιδιων
Kaur et al. DMA, a bisbenzimidazole, offers radioprotection by promoting NFκB transactivation through NIK/IKK in human glioma cells
Fernandes et al. Tumor malignancy is engaged to prokaryotic homolog toolbox
WO2008109519A3 (en) Micro-rna profiles associated with endometrial cancer
Chen et al. Prognostic and diagnostic potential of isocitrate dehydrogenase 1 in esophageal squamous cell carcinoma
Djunic et al. Prognostic risk score for the survival of elderly patients with acute myeloid leukaemia comprising comorbidities
Chianese et al. Epigenomic machinery regulating pediatric AML: clonal expansion mechanisms, therapies, and future perspectives

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]